FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine and aims at preventing and treating respiratory diseases, disorders or conditions. Implementing a method for preventing or treating the respiratory diseases, disorders or conditions involves administering a therapeutically effective amount of tetomilast and at least one beta2-adrenoreceptor agonist into the patient. According to the other embodiment, tetomilast and at least one beta2-adrenoreceptor agonist are administered together with at least one anti-inflammatory steroid. What is also presented is a pharmaceutical composition containing tetomilast and at least one beta2-adrenoreceptor agonist.
EFFECT: using the declared group of inventions provides the more effective prevention and treatments of respiratory diseases, disorders or conditions.
46 cl, 3 dwg, 6 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF TREATING OR PREVENTING ASTHMA BY ADMINISTERING IL-4R ANTAGONIST | 2015 |
|
RU2713406C2 |
| METHODS, COMPOSITIONS AND PREPARATIONS FOR TREATING THYROID-ASSOCIATED OPHTHALMOPATHY | 2007 |
|
RU2417100C2 |
| PREPARATIONS FOR TREATING ADIPOSE TISSUE, SKIN TISSUE AND DISORDERS, AND MUSCULAR TISSUE | 2007 |
|
RU2420317C2 |
| COMBINATION OF METHYLXANTHINE COMPOUNDS AND STEROIDS FOR TREATMENT OF CHRONIC RESPIRATORY DISEASES | 2006 |
|
RU2395285C2 |
| PROLONGED RELEASE LIPOLYTIC COMPOUNDS FOR LOCAL TREATMENT OF LIPOPEXIA | 2006 |
|
RU2431501C2 |
| METHODS OF TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-33 ANTAGONIST | 2020 |
|
RU2838119C2 |
| METHODS FOR TREATMENT OR PREVENTION OF ASTHMA BY ADMINISTERING IL-4R ANTAGONIST | 2013 |
|
RU2690675C2 |
| CATIONS OF MONOVALENT METALS OF DRY POWDERS FOR INHALATIONS | 2011 |
|
RU2640921C2 |
| 5-(2-{[6-(2,2-DIFLURO-2-PHENYLETHOXY)HEXYL]AMINO}-1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE HEMINAPADISYLATE AS β2 ADRENERGIC RECEPTOR AGONIST | 2008 |
|
RU2495029C2 |
| NEW DOSE AND FORMULATION | 2009 |
|
RU2608713C2 |
